J Med Virol . Management of SARS-CoV-2 Pneumonia

[tetano]

J Med Virol


. 2020 Aug 28.
doi: 10.1002/jmv.26470. Online ahead of print.
Management of SARS-CoV-2 Pneumonia


Caterina Sagnelli ¹ , Benito Celia ² , Caterina Monari ¹ , Salvatore Cirillo ² , Giulia De Angelis ¹ , Andrea Bianco ² , Nicola Coppola ¹



Affiliations

• PMID: 32856728
• DOI: 10.1002/jmv.26470

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread throughout the world since December 2019 to become a global public health emergency for the elevated deaths and hospitalizations in Intensive Care Units. The severity spectrum of SARS-CoV-2 pneumonia ranges from mild to severe clinical conditions. The clinical course of SARS-CoV-2 disease is correlated with multiple factors including host characteristics (genetics, immune status, age and general health), viral load and, above all, the host distribution of the airways and lungs of the viral receptor cells. In this review, we will briefly summarize the current knowledge on the characteristics and management of COVID-19-pneumonia. However, other studies are needed to better understand the pathogenetic mechanisms induced by SARS-Cov-2 infection, and to evaluate the long-term consequences of the virus on the lungs. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; SARS-CoV-2; clinical presentation; pneumonia.